New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
07:38 EDTARIAARIAD announces FDA acceptance of NDA filing for Ponatinib
ARIAD Pharmaceuticals announced that the FDA has accepted for filing the New Drug Application for accelerated review of ARIADís investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia or Philadelphia-chromosome positive acute lymphoblastic leukemia. The FDA also has granted ARIADís request for Priority Review, which is given to investigational medicines that have the potential for providing significant improvement in the treatment, prevention, or diagnosis of a disease. The FDA has established an action date of March 27, 2013 under the Prescription Drug User Fee Act.
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
12:37 EDTARIASarissa says ARIAD denied 'poison pill' waiver request
Subscribe for More Information
August 25, 2014
12:37 EDTARIAARIAD ICLUSIG prescriptions encouraging, says BMO Capital
Subscribe for More Information
10:40 EDTARIABiotechs rise after InterMune acquired by Roche
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use